O0383
油酰单乙醇胺
~98% (TLC), PPARα agonist, powder
别名:
N-（羟乙基）油酰胺, N-（顺式-9-十八碳烯酰基）乙醇胺, OEA, 油酰乙醇胺
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H39NO2
化学文摘社编号:
分子量:
325.53
NACRES:
NA.83
PubChem Substance ID:
UNSPSC Code:
12352204
EC Number:
203-884-8
MDL number:
产品名称
油酰单乙醇胺, ~98% (TLC)
InChI
1S/C20H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)21-18-19-22/h9-10,22H,2-8,11-19H2,1H3,(H,21,23)/b10-9-
InChI key
BOWVQLFMWHZBEF-KTKRTIGZSA-N
SMILES string
O=C(CCCCCCC/C=C\CCCCCCCC)NCCO
assay
~98% (TLC)
form
powder
solubility
chloroform: 20 mg/mL, clear, colorless
storage temp.
−20°C
Quality Level
Gene Information
human ... CNR1(1268), CNR2(1269), PPARA(5465), TRPV1(7442)
mouse ... Cnr2(12802)
rat ... Cnr1(25248)
正在寻找类似产品? 访问 产品对比指南
相关类别
General description
油酰乙醇胺（OEA）是一种内源性脂肪酸乙醇胺。小肠细胞、脂肪组织、神经元和星形胶质细胞可产生OEA。
Application
N-油酰乙醇胺已用于研究其对胰高血糖素样肽（GLP）-1RA介导的厌食信号传导和体重减轻的影响。
Biochem/physiol Actions
油酰乙醇胺（OEA）是一种脂质介体，有助于控制各种生物功能，例如食物摄取。它调节小肠中的基因表达。OEA能够引发产生多种受体，例如1型大麻素受体（CB1）、过氧化物酶体增殖物激活受体（PPAR）和G蛋白偶联受体119（GPR119）。
过氧化物酶体增殖物激活受体α （PPARα ）激动剂
存储类别
11 - Combustible Solids
wgk
WGK 2
ppe
dust mask type N95 (US), Eyeshields, Gloves
The Neurotrophic Effect of Oleic Acid: Implications for Olive Oil in Health and Disease
Olives and Olive Oil in Health and Disease Prevention, 1405-1412 (2010)
Gustavo Provensi et al.
The international journal of neuropsychopharmacology, 20(5), 392-399 (2017-03-25)
The integrity of the brain histaminergic system is necessary for the unfolding of homeostatic and cognitive processes through the recruitment of alternative circuits with distinct temporal patterns. We recently demonstrated that the fat-sensing lipid mediator oleoylethanolamide indirectly activates histaminergic neurons
Lea Tischmann et al.
Nutrients, 12(5) (2020-05-28)
An unfavorable lipid profile and being overweight are known mediators in the development of cardiovascular disease (CVD) risk. The effect of diet, particularly high in protein, remains under discussion. Therefore, this study examines the effects of a high-protein (HP) diet
Tom H Johnston et al.
The Journal of pharmacology and experimental therapeutics, 336(2), 423-430 (2010-10-23)
Dopaminergic therapies remain the most efficacious symptomatic treatments for Parkinson's disease (PD) but are associated with motor complications, including dyskinesia, and nonmotor complications, such as psychosis, impulse control disorders (ICD), and dopamine dysregulation syndrome (DDS). Nondopaminergic neurotransmitter systems, including the
Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice
Brown JD, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 315(4), R595-R608 (2018)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持